Klin Farmakol Farm. 2019;33(3):41-45 | DOI: 10.36290/far.2019.022

Ceftolozane/tazobactam in treating multifocal infection caused by a multiresistant Pseudomonas aeruginosa strain in a severely burned patient

Břetislav Lipový1,2, Markéta Hanslianová3, Yvona Kaloudová1, Hana Řihová1, Martin Knoz1,2,4, Jakub Holoubek1,2, Ivan Suchánek1
1 Klinika popálenin a plastické chirurgie FN Brno
2 Lékařská fakulta, Masarykova univerzita Brno
3 Oddělení lékařské mikrobiologie FN Brno
4 Klinika plastické a estetické chirurgie FN u Svaté Anny, Brno

Ceftolozane/tazobactam is an antibiotic combining a novel cephalosporin with a beta-lactamase inhibitor. Complicated intra-abdominal infections and complicated urinary tract infections are basic indications for the use of this antibiotic. There has also been increasing evidence of high efficacy of ceftolozane/tazobactam in treating infectious complications in other compartments, particularly in the case of infections with resistant Pseudomonas aeruginosa strains. Treatment of infectious complications caused by this pathogen is very challenging, often requiring a major compromise between an approved indication and efficacy. The case report presents a severely burned young man with a multifocal infection caused by multiresistant Pseudomonas aeruginosa.

Keywords: ceftolozane, tazobactam, multiresistant Pseudomonas aeruginosa, burns

Published: October 28, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lipový B, Hanslianová M, Kaloudová Y, Řihová H, Knoz M, Holoubek J, Suchánek I. Ceftolozane/tazobactam in treating multifocal infection caused by a multiresistant Pseudomonas aeruginosa strain in a severely burned patient. Klin Farmakol Farm. 2019;33(3):41-45. doi: 10.36290/far.2019.022.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Decraene V, Ghebrehewet S, Dardamissis E, et al. An outbreak of multidrug-resistant Pseudomonas aeruginosa in a burns service in the North of England: challenges of infection prevention and control in a complex setting. J Hosp Infect. 2018 Dec; 100(4): e239-e245. doi: 10.1016/j.jhin.2018.07.012. Go to original source... Go to PubMed...
    2. Slaviero L, Avruscio G, Vindigni V, Tocco-Tussardi I. Antiseptics for burns: a review of the evidence. Ann Burns Fire Disasters. 2018 Sep 30; 31(3): 198-203.
    3. Wang Y, Beekman J, Hew J, Jackson S, Issler-Fisher AC, Parungao R, Lajevardi SS, Li Z, Maitz PKM. Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring. Adv Drug Deliv Rev. 2018 Jan 1; 123: 3-17. doi: 10.1016/j.addr.2017.09.018. Go to original source... Go to PubMed...
    4. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/Tazobactam: A Novel Cephalosporin/?-Lactamase Inhibitor Combination. Pharmacotherapy. 2015 Jul; 35(7): 701-715. doi: 10.1002/phar.1609. Go to original source... Go to PubMed...
    5. Larson KB, Patel YT, Willavize S, Bradley JS, Rhee EG, Caro L, Rizk ML. Ceftolozane/tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intraabdominal infections. Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.02578-18. doi: 10.1128/AAC.02578-18. Go to original source... Go to PubMed...
    6. Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Int J Antimicrob Agents. 2018 Feb; 51(2): 181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Go to original source... Go to PubMed...
    7. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2017 Jun 27; 61(7). pii: e00465-17. doi: 10.1128/AAC.00465-17. Go to original source... Go to PubMed...
    8. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect, DiS. 2016 Sep 1; 63(5): e61-e111. doi: 10.1093/cid/ciw353. Go to original source... Go to PubMed...
    9. Sousa Dominguez A, Perez-Rodríguez MT, Nodar A, Martinez-Lamas L, Perez-Landeiro A, Crespo Casal M. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam. J Antimicrob Chemother. 2017 Apr 1; 72(4): 1262-1263. doi: 10.1093/jac/dkw526. Go to original source... Go to PubMed...
    10. Castaldo N, Givone F, Peghin M, Righi E, Sartor A, Bassetti M. Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam. J Glob Antimicrob Resist. 2017 Jun; 9: 100-102. doi: 10.1016/j.jgar.2017.02.012. Go to original source... Go to PubMed...
    11. Dietl B, Sánchez I, Arcenillas P, et al. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes. Int J Antimicrob Agents. 2018 Mar; 51(3): 498-502. doi: 10.1016/j.ijantimicag.2017.11.003. Go to original source... Go to PubMed...
    12. Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, Borgia G. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy. J Antimicrob Chemother. 2017 Sep 1; 72(9): 2678-2679. doi: 10.1093/jac/dkx172. Go to original source... Go to PubMed...
    13. Skoglund E, Ledesma KR, Lasco TM, Tam VH. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 Dec; 11: 154-155. doi: 10.1016/j.jgar.2017.10.016. Go to original source... Go to PubMed...
    14. Aitken SL, Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, Nicolau DP, Nunez CA. Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient. Pediatr Infect Dis J. 2016 Sep; 35(9): 1040-1042. doi: 10.1097/INF.0000000000001228. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.